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Abstract   
 
Background: Benzodiazepines and anticholinergic drugs have been implicated in 
causing cognitive decline and potentially increasing dementia risk. However, evidence 
for an association with neuropathology is limited.  
 
Objective: to estimate the correlation between neuropathology at death and prior use 
of benzodiazepines and anticholinergic drugs. 
 
Methods: We categorised 298 brain donors from the population-based Medical 
Research Council Cognitive Function and Ageing Study, according to their history of 
benzodiazepine (including Z-drugs) or anticholinergic medication (drugs scoring 3 on 
the Anticholinergic Cognitive Burden scale) use. We used logistic regression to 
compare dichotomised neuropathological features for those with and without history 
of benzodiazepine and anticholinergic drug use before dementia, adjusted for 
confounders. 
  
Results: Forty-nine (16%) and 51 (17%) participants reported benzodiazepine and 
anticholinergic drug use. Alzheimer’s disease neuropathologic change was similar 
whether or not exposed to either drug, for example 46% and 57% had 
intermediate/high levels among those with and without anticholinergic drug use. 
Although not significant after multiple testing adjustments, we estimated an odds ratio 
(OR) of 0.40 (95% confidence interval [95%CI] 0.18-0.87) for anticholinergic use and 
cortical atrophy. For benzodiazepine use, we estimated ORs of 4.63 (1.11-19.24) and 
3.30 (1.02–10.68) for neuronal loss in the nucleus basalis and substantial nigra. There 
 4 
 
was evidence of neuronal loss in the nucleus basalis with anticholinergic drug use, but 
the association reduced when adjusted for confounders.  
 
Conclusions: We found no evidence that benzodiazepine or anticholinergic drug use 
is associated with typical pathological features of Alzheimer’s disease, however we 
cannot rule out effects owing to small numbers. 
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INTRODUCTION  
Drugs with anticholinergic activity (henceforth ‘anticholinergics’) block the 
neurotransmitter acetylcholine in the central or peripheral nervous system, affecting 
multiple body functions.  Patients with a wide range of conditions such as urinary 
incontinence, Parkinson’s disease, depression, epilepsy, gastrointestinal disorders 
and allergies may take drugs that have anticholinergic properties.  Acetylcholine is 
strongly linked to learning and memory [1], and reductions in markers of the cholinergic 
system are found in both Alzheimer’s Disease and Lewy body dementias, and 
correlate with cognitive decline [2]. Observational studies have suggested that long-
term use of anticholinergic drugs increases the risk of developing dementia [3,4]. 
 
Benzodiazepines and related drugs including, zaleplon, zolpidem and zopiclone 
(referred to as Z-drugs) are commonly prescribed for anxiety and insomnia in older 
people. In the US, 9% of older adults currently use benzodiazepines, with 31% of these 
being long-term users [5]. Despite the well documented acute cognitive impairment 
associated with benzodiazepines, other side-effects including increased falls risk, 
tolerance and addiction, they are still used for long durations and at doses that exceed 
recommended limits [6]. Whilst earlier studies suggested long-term benzodiazepine 
use was associated with greater incidence of dementia, later studies do not [7–9]. 
 
Few studies have examined neuropathological correlates of long-term anticholinergic 
drug use. Increased Alzheimer’s disease pathology (both amyloid plaque and 
neurofibrillary tangle densities) has been observed in Parkinson’s disease patients 
with continuous use of anticholinergic drugs for at least 2 years [10]. Alzheimer’s 
disease pathology, inflammation and other neurodegeneration have been linked to 
 6 
 
anticholinergics in animal studies [11–13].  However a recent community-based 
autopsy study in humans reported no association between Alzheimer’s disease-
related neuropathological changes and anticholinergic use [14].  
 
Studies examining the neuropathological consequences of benzodiazepine use are 
scarce [15]. An imaging study reported decreased amyloid load with chronic 
benzodiazepine use [15]. It is speculated that upregulating or preserving GABAAγ1/3 
and γ2 receptors may protect neurons against neurofibrillary pathology in Alzheimer’s 
Disease [16]. Theories vary as to whether benzodiazepine use may decrease or 
increase cognitive reserve [17,18]. In addition, benzodiazepines are considered to 
affect the α5-containing GABA(A) receptors, which are involved in cognition and 
preferentially located in the hippocampus [19].  
 
In short, while there is some epidemiologic evidence of links between the use of 
anticholinergics and benzodiazepines with clinical outcomes such as subsequent 
cognitive decline and incident dementia [3,14,20,21], findings to date have been 
mixed, subject to potential biases and have little direct mechanistic support.  In this 
study we test the hypothesis that the use of either class of drug in later life but prior to 
any dementia diagnosis is associated with the presence of neuropathologic features 
at autopsy, among a population representative cohort of older adults who agreed to 
brain donation upon death. 
 
MATERIALS AND METHODS 
The Medical Research Council Cognitive Function and Ageing Study (CFAS) is a 
multi-centre longitudinal population-based study of people aged 65 years and older in 
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England and Wales. The five centres (Cambridge, Gwynedd, Newcastle upon Tyne, 
Nottingham and Oxford) used identical methods to assess participants. Details of the 
study design have been described previously [22,23], but in short participants were 
selected at random from primary care lists in each of the five areas, and each was 
visited by an interviewer who recruited selected individuals into the study and 
conducted a baseline assessment. At baseline, trained interviewers completed a 
standardised questionnaire with participants that included sociodemographic and 
health questions and the Mini-mental State Examination (MMSE) [24]. A stratified 
sample of 20% was selected for more detailed evaluations that included a further 
participant interview and an interview with an informant. The participant interview 
included the full GMS-AGECAT diagnostic algorithm (equivalent to that in the 
Diagnostic and Statistical Manual of Mental Disorders, third edition, revised [DSM-III-
R]) [25], and the Cambridge Cognitive Examination (CAMCOG) which is part of the 
Cambridge Medical Examination for the Elderly (CAMDEX) interviews [26]. 
Respondents were re-interviewed bi-annually with some follow-ups annually. When 
needed, interviews were assisted by an informant. 
 
A brain donation programme was incorporated into all centres and predominantly 
focused on the detailed assessment arm of the study. The donor cohort is similar to 
the main study sample in all respects, other than those selected for invitation were 
weighted towards the cognitively impaired [27].  A retrospective informant interview 
(RINI) was conducted to ascertain the cognitive and health status of brain donors in 
the period between the last scheduled CFAS interview and death.  MRC CFAS 
received multi-centre research ethics committee approval (Ref: 05/MRE05/37). 
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Dementia Diagnosis 
Dementia status during each interview was derived using the full AGECAT diagnostic 
algorithm, defined as an organicity rating of level 3 or above [25,28]. This is equivalent 
to dementia as diagnosed by DSM-III-R [25]. Dementia at death was classified 
including information from the survey interviews, as well as interviews with informants 
after the respondent's death when this was possible, and death certification [29].  
 
Neuropathology  
Post-mortem tissue was obtained from respondents who signed a Declaration of Intent 
(DOI) to donate their brain after death and among whom a successful donation was 
then made. The neuropathologic assessment was carried out by clinical 
neuropathologists over the course of the CFAS study and the methods have been 
described elsewhere [27,29]. Briefly, macroscopic lesions, including infarcts, and focal 
and global atrophy (coded as none, mild, moderate or severe) were assessed at brain 
dissection. Depending on the centre, portions of brain tissue (either samples or slices 
of hemi-brain) were flash frozen and the remained fixed in formalin and sampled into 
paraffin blocks for the production of sections for histological assessment. Samples 
from the four neocortical areas, cingulate, hippocampus, basal ganglia, midbrain, 
pons, medulla and cerebellum were assessed following the protocol of the Consortium 
to Establish a Registry of Alzheimer's Disease (CERAD) with modification to include 
additional neurodegenerative and vascular pathology (see www.cfas.ac.uk) [30].  
 
Alzheimer’s disease neuropathologic change was measured using the ‘ABC’ score 
and categorised into high/intermediate or not/low [31].  Plaques were assessed using 
the CERAD method [30], and the maximum cortical neuritic plaque score calculated. 
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The neuroanatomical spread of neurofibrillary tangles (NFTs) was assessed according 
to Braak NFT staging, the six stages of which allow the neuroanatomical extent of 
NFTs to be classified into entorhinal (stages I-II), limbic (III-IV) and isocortical (V-VI) 
stages [32]. Assessment of Aβ phase was performed according to the Thal scheme 
[33], but only in the Cambridge and Newcastle centres [34]. Cerebral amyloid 
angiopathy (CAA) in leptomeningeal and parenchymal vessels was also assessed as 
none, mild, moderate or severe in each of the brain areas. 
 
Other measures including macro and microvascular disease were documented, as 
well as neuronal loss in the hippocampus, entorhinal cortex, nucleus basalis, 
substantia nigra and locus ceruleus noted as none, mild, moderate or severe. 
Microinfarcts were recorded as any assessed in brain areas of the cortex (frontal 
cortex, temporal cortex, parietal cortex, occipital cortex, cingulate cortex, insular 
cortex, hippocampus [level of lateral geniculate body], entorhinal cortex and 
amygdala, cerebellar cortex) and separately in the subcortex (basal ganglia, midbrain, 
pons and medulla) [35]. White matter lesions were semi-quantified using post mortem 
MRI in three brain slices, and scored using the Schelten’s scoring scheme [36].  
 
Neuropathological examination was completed blind to clinical and interview data. 
Inter-rater reliability assessed by circulation of macroscopic brain photographs and 
microscopic slides among contributing pathologists was acceptable (<5% with scores 
more than 1 grade difference) [37]. 
 
Drug exposure 
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At each interview, participants were asked about their current use of medication with 
the question: ‘‘Do you take any medicine, tablets or injections of any kind, either that 
you buy yourself or that are prescribed by your doctor?’’ Drug name, dose, and 
frequency were recorded for each reported medication. We classified whether 
participants reported use (“any” anticholinergic use) of a drug scoring 3 on the 
Anticholinergic Cognitive Burden scale [38], and whether they reported use at more 
than one interview (“recurrent” use) occurring before one year prior to a dementia 
diagnosis. Similarly, we classified participants as having any use or recurrent users of 
a benzodiazepine (including Z-drugs). Interviews with drug data assessed included: 
baseline, 1-year, 2-year, 3-year, 6-year, 8-year, 10-year, 12-year, 14-year and 16-year 
follow-up. The number of interviews a patient completed depended on when they died, 
were recruited, met the dementia diagnosis criteria, and whether they were in the 
assessment arm with more frequent interviews. Participants were included in the 
analysis if they completed at least two interviews before one year prior to dementia 
diagnosis or death.  
 
Statistical Analysis  
Participant characteristics were compared across those reporting or not reporting 
anticholinergic drug use and benzodiazepine use.  Neuropathology measures 
categorised by severity were dichotomised into moderate/severe or not, and low 
brain weight was defined as 1254<kg for men and 1120<kg for women. Analyses 
were later preformed instead using sex-standardised brain weight (measured as a 
continuous variable), with no effect on the study findings (results not shown). The 
association between each dichotomised pathological feature with levels of 
anticholinergic and benzodiazepine use was estimated using logistic regression.  
 11 
 
Initial models were adjusted only for adjusting for age at death and sex. Further 
multivariable models included both anticholinergic and benzodiazepine exposure and 
were also adjusted for education (≤9 or 10+ years), baseline comorbidity (stroke, 
diagnosed hypertension, depression/anxiety, Parkinson’s disease, and asthma), 
baseline sleep problems, and number of medication interviews completed.  
 
Ordinal logistic regression was similarly used to estimate ORs for greater Braak 
staging and categorised Thal phase (0, 1-2, 3, 4-5) according to drug exposure. The 
proportional odds assumption was tested using the Brant test.  
 
All analyses were performed using Stata version 15.1. Statistical significance was 
defined as p<0.05 on a two-sided test. However, due to the many neuropathological 
outcomes tested, we also used the Benjamini-Hochberg procedure to estimate the 
critical p-value threshold in order to control the false discovery rate (i.e. the proportion 
of rejected null hypotheses that are incorrect rejections) to less than 20% [39].   
 
RESULTS 
MRC CFAS recruited 13,004 participants, among whom 401 brain donations were 
successfully made by August 2015, and of whom 337 had two or more interviews 
recording medication data before death. Of these, 298 completed at least two 
interviews at least one year before meeting the dementia diagnosis or death, hence 
were included in our study. The median (inter-quartile range) duration in the study was 
9 (5-13) years and the mean (standard deviation) number of interviews with medication 
exposure recorded was 4.2 (2.0).  
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Of the 298 brain donors, 51 (17%) participants reported anticholinergic use at at least 
one interview and 35 (12%) reported recurrent use. Of these, 33 (11%) reported 
antidepressant use, 11 (4%) reported urologicals, 2 (<1%) reported antiparkinson 
drugs, 3 (1%) reported antipsychotics and 4 (1%) reported antihistamines. Forty nine 
(15%) participants reported any benzodiazepine or Z-drug use and 33 (11%) reported 
recurrent use. This included 46 (16%) participants reporting  benzodiazepine use and 
5 (2%) reporting Z-drug use.  Of the 83 participants reporting either benzodiazepine 
or anticholinergic drug use, 17 (20%) participants reported both. 
 
At death, the mean (SD) age of the brain donors was 86.2 (7.4) years, 175 (59%) were 
women, and 102 (34%) had dementia. Those reporting benzodiazepine use, 
anticholinergic drug use and no use were generally similar in terms of time between 
recruitment and death, and in the proportions dying with dementia, or reporting stroke, 
asthma and hypertension during interviews (Table 1).  However participants reporting 
anticholinergic drug use were younger at death, had less education, and were more 
likely to have depression, anxiety or Parkinson’s disease.  Those reporting 
benzodiazepine use were more likely to be women and have depression or sleep 
problems.  
 
Neuropathological correlates of anticholinergic drug use 
In general, there was no evidence of any associations between the distribution of 
neuropathology and anticholinergic medication use.  In terms of statistical significance, 
no associations between anticholinergic drug use and any neuropathological features 
were detected after taking into account the multiple features tested, at the revised 
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critical threshold of p<0.008 (table 2). However, our findings are consistent with a wide 
range of effect sizes for many of the variables tested. 
 
With respect to Alzheimer’s disease neuropathologic change, 117 of 207 (57%) non-
users had intermediate/high levels at autopsy compared to 22 of 48 (46%)  
anticholinergic users.  Mean Braak stage was also similar between those who never 
reported anticholinergics (mean [SD] = 2.6 [1.6]), those who reported anticholinergic 
use once (2.1 [1.7]) and those reporting use more than once (2.7 [1.6]). 
 
Although not significant after accounting for multiple testing, fewer cases of cortical 
atrophy were observed in anticholinergic drug users compared to non-users (adjusted 
OR=0.40, 95% CI 0.18 - 0.87), and even fewer were observed for recurrent users 
(adjusted OR=0.26, 95% CI 0.09 - 0.70). Neuronal loss in the nucleus basalis was 
more common with anticholinergic drug use when only adjusted for age and sex 
(OR=3.52, 95% CI 1.03-12.05), but this associated reduced when fully adjusted for 
the covariates (OR=2.06, 95% CI 0.49-8.68). There were no associations with 
macroscopic or microscopic cerebrovascular disease and anticholinergic use.  
 
 
Neuropathological correlates of benzodiazepine use 
No neuropathological features were more common with benzodiazepine drug use 
history after taking into account the multiple features tested (table 3). Comparable 
levels of Alzheimer’s disease neuropathologic change was observed between non-
users (53% with intermediate/high levels) and benzodiazepine users (64% with 
intermediate/high levels) at autopsy. Although not significant after accounting for 
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multiple testing, we estimated adjusted ORs for benzodiazepine use and neuronal 
loss in the entorhinal cortex, nucleus basalis, and substantia nigra of 2.47 (95% CI 
0.90 – 6.76), 4.63 (95% CI 1.11 – 19.24) and 3.30 (95% CI 1.02 – 10.68), which 
were similar or stronger for recurrent benzodiazepine use. There was also 
suggestion of reduced cortical microinfarcts with longer benzodiazepine use 
(adjusted OR for recurrent use =0.11, 95% CI 0.02-0.63).  
 
DISCUSSION 
We found no association between anticholinergic use and pathological features typical 
of Alzheimer’s disease. However, our findings are internally consistent with a wide 
range of effect sizes for many of the variables tested. Although not significant after 
accounting for multiple testing, we observed evidence of less cortical atrophy with 
anticholinergic use and less cortical microinfarcts with benzodiazepine use.  We also 
observed evidence of neuronal loss in the entorhinal cortex nucleus basalis and 
substantial nigra with benzodiazepine use. 
 
Our findings are similar to that of the Adult Changes in Thought study in finding no 
association between recurrent anticholinergic use and Alzheimer’s disease 
neuropathological lesions [14], unlike suggestions from previous studies [10][11,12]. 
Reduced total cortical volume and temporal lobe cortical thickness and greater lateral 
ventricle and inferior lateral ventricle volumes were observed in patients treated with 
anticholinergics in a US Alzheimer’s Disease Neuroimaging Initiative (ADNI) study 
[40]. However, we found evidence of decreased cortical atrophy and no evidence of 
temporal lobe atrophy in patients treated with anticholinergics.  Our cortical atrophy 
measure likely represents synaptic and (to a lesser extent) neuronal loss and is a non-
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specific effect of pathologies damaging neurons. Macroscopic atrophy and brain 
weight likely reflect synaptic loss and unlike typical Alzheimer’s Disease 
neuropathology remain associated with dementia across the late-life spectrum [29]. 
Our findings are internally consistent with evidence towards associations of fewer 
CAA, cortical atrophy, Alzheimer’s Disease neuropathology, and greater brain weight 
with anticholinergic use [41]. Whilst the underlying mechanism is uncertain, they do 
not point towards greater Alzheimer’s Disease neuropathology with higher levels of 
anticholinergic drug use.  
 
Our findings are consistent with the US Baltimore Longitudinal Study of Aging study 
that reported no effect of strong anticholinergic drug use on cortical grey matter volume 
using MRI [42]. We found no association between anticholinergic use and reduced 
microinfarct burden, contrary to the Adult Changes in Thought study [14], but found 
evidence of reduced cortical microinfarct burden with greater benzodiazepine use.  
Findings from pathology studies may vary due to differences in populations and the 
small numbers of participants included, differences in outcome measurement (e.g. 
MRI during life or pathology at death) and the specific methods for neuropathology 
measurement and classification, medication exposure measurement (e.g. current use 
or prescription or cumulative past use, or definition of anticholinergic), and in analytic 
approach and control for confounding.  Regional vulnerability in the hippocampus 
could also play a role in the discrepancies between the various pathological studies 
examining the relationship between long-term anticholinergics exposure and AD 
pathology, however we were unable to examine this in our dataset  [43].   
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Our findings of potentially greater neuronal loss in the nucleus basalis with both 
anticholinergic and benzodiazepine use are of interest. The nucleus basalis is rich in 
acetylcholine and stimulates the cholinergic system of the neocortex [44]. Neuronal 
loss in this region is thought to occur in the early stages of Alzheimer’s disease [45–
47]. It is reasonable to believe anticholinergic drugs could contribute towards 
neuronal loss in the nucleus basalis, as studies have identified that these neurons 
are susceptible to other toxic agents such as cadmium, aluminium, nitric oxide and 
ethanol [48–50]. However, reverse causation might also underlie this relationship.  
Loss of stimulation to the cholinergic system has been reported to lead to the 
development of psychiatric and behavioral symptoms termed ‘Cholinergic Deficiency 
Syndrome’ including agitation, anxiety, apathy, delusions, hallucinations and 
irritability [51–53][44]. Given that the strongest associations were observed for 
anticholinergic antidepressants, antipsychotics and benzodiazepines and neuronal 
loss in the nucleus basalis (results not shown), it may be that these drugs were 
prescribed to treat the symptoms of ‘Cholinergic Deficiency Syndrome’. Other 
studies suggest that volume loss in the basal forebrain cholinergic system leads to 
widespread cortical atrophy in MCI patients [54], however we did not observe 
widespread cortical atrophy in our study.   
 
Our study does not support the hypothesis that anticholinergic drug use contributes 
towards Alzheimer’s Disease neuropathological lesion formation. A potential 
mechanism is highlighted whereby these drugs could impact on early stages of 
Alzheimer’s Disease development via neuronal loss in the basal forebrain. However, 
it is more likely that anticholinergic exposure leads to more accelerated cognitive 
aging rather than to greater Alzheimer’s disease pathology. A review concluded that 
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despite limited human data, tauopathy mouse models indicate anticholinergic drugs 
may enhance neurodegeneration with enhanced neuroinflammation including 
microglial activation [55]. 
 
The study benefits from being population-based with a long data history available 
before autopsy. Brain donors were found generally representative of the main study, 
except for being weighted towards the cognitively impaired by design [27]. The 
method used for diagnosing dementia has been validated and is widely used [56,57]. 
Detailed information was available from the interviews allowing us to use 
multivariable statistical techniques to reduce confounding and account for various 
indications for the drugs. 
 
A major limitation of this study and other similar research based on brain banks is 
that our outcome measures can only be made at autopsy after death.  Additionally, 
the cause and timing of death is likely to influence on the degree of pathology in the 
brain.  To reduce this we adjusted for age at death and number of interviews, so that 
the effects of reported exposure are not confounded by the number of opportunities 
to report exposure, nor the age of the participant at the time of the outcome 
measurement. Although the neuropathological data was obtained using a 
standardised protocol and blind to any clinical information, we were limited by the 
historical measures available and future studies could benefit from more targeted 
measures. We assessed Alzheimer’s diease neuropathologic change using the 
‘ABC’ score and its component scores to reduce the impact of any interreater 
variability in plaque and tangle counts [31]. We were limited by not having Thal 
phase evaluated for all donors, however Thal phase is highly correlated with Braak 
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stage and neuritic plaque score and has been shown to provide little improvement in 
predicting dementia beyond these [34]. 
 
The small numbers of participants reporting anticholinergic and benzodiazepine use 
limited the statistical power of the study. None of the associations were statistically 
significant after correction to control the false discovery rate to less than 0.20. We 
lacked detailed information on drug exposure; for example, duration taking or 
prescribed the drugs was not recorded. Non-adherence is common is this population 
and we lacked data on drug adherence [58]. However, we are more confident that 
the participants took the drugs than in studies relying on prescription data, as use 
was self-reported and interviewers asked to see drug packages. Drug use was only 
recorded on the date of the intermittent surveys; hence we will have under-reported 
anticholinergic and benzodiazepine drug use. Misclassification of exposures in this 
way would be expected to weaken any associations detected.  However, we tend to 
find good concordance in reports of drug use between successive assessments, 
suggesting that assessments are reasonably representative of medication use 
throughout the exposure period. 
 
Our findings and those of others in this area highlight the limitations of current 
neuropathology databases for investigating the causes of brain changes, as well as 
suggesting important areas for future research. Further research is needed whether 
and how use of long-term drug use might lead to neuronal loss, or whether, as 
seems equally likely, drug use follows early changes in the brain which are only 
detected later on autopsy. 
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Tables and Figures 
 
Table 1. Characteristics of the brain donors by benzodiazepine and anticholinergic drug history 
 
 
Anticholinergic 
use (n=51) 
No anticholinergic 
use (n=247)   
Benzodiazepine 
use (n=49) 
No benzodiazepine 
use (n=249) 
Baseline characteristics n % n %   n % n % 
Women 33 64.7 142 57.5  36 73.5 139 55.8 
Age at baseline, years* 73.8 7.5 77.2 6.8  79.3 7.8 76.1 6.8 
Age at death, years* 84.7 7.1 86.7 7.3  87.7 6.8 85.9 7.3 
Education, years* 9.4 1.7 9.9 2.1  9.7 1.7 9.8 2.1 
Smoker  14 27.5 43 17.4  10 20.4 47 18.9 
Duration in study, years* 9.7 5.8 9.1 4.6  9.1 5 9.2 4.9 
Assessment arm 33 64.7 110 44.5  25 51 118 47.4 
Centre          
Cambridge 17 33.3 59 23.9  18 36.7 58 23.3 
Gwynedd 4 7.8 11 4.5  3 6.1 12 4.8 
Newcastle 11 21.6 36 14.6  8 16.3 39 15.7 
Nottingham 17 33.3 96 38.9  15 30.6 98 39.4 
Oxford 2 3.9 45 18.2  5 10.2 42 16.9 
Health conditions          
Depression 10 19.6 22 8.9  11 22.4 21 8.4 
Anxiety 8 15.7 17 6.9  6 12.2 19 7.6 
Asthma 9 17.6 22 8.9  6 12.2 25 10 
Hypertension 23 45.1 87 35.2  14 28.6 96 38.6 
Parkinson's disease 3 5.9 3 1.2  3 6.1 3 1.2 
Stroke 7 13.7 21 8.5  5 10.2 23 9.2 
Sleep problems 24 47.1 82 33.2  29 59.2 77 30.9 
Duration of sleep problems, years^ 9 4-23 8 4-15  11 6-24 7 4-14 
Dementia at death 15 29.4 87 35.2   19 38.8 83 33.3 
 
* mean (SD) 
^ median (IQR) 
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Table 2. Adjusted odds ratios for anticholinergic drug use reported before dementia and neuropathology outcomes 
 
    Anticholinergic use, n(%) OR (95% CI), age and sex adjusted   OR (95% CI), fully adjusted
a 
Neuropathology outcome None (n=247) Once (n=16) 
Recurrent 
(n=35) 
Any 
anticholinergic 
use 
Recurrent 
anticholinergic 
use 
 
Any 
anticholinergic 
use 
Recurrent 
anticholinergic 
use 
Low brain weight 84 34.1 3 18.8 8 23.5 0.59 (0.29 - 1.23) 0.62 (0.27 - 1.44)  0.55 (0.25 - 1.21) 0.51 (0.20 - 1.31) 
Alzheimer’s disease pathology       
     
Intermediate/high AD neuropathologic 
change 
117 56.5 6 37.5 16 50.0 0.73 (0.38 - 1.40) 0.79 (0.37 - 1.68) 
 
0.57 (0.27 - 1.20) 0.48 (0.20 - 1.19) 
Cortical neuritic plaquesb 68 28.2 5 31.3 7 22.6 0.89 (0.43 - 1.82) 0.73 (0.30 - 1.79)  0.85 (0.38 - 1.93) 0.71 (0.26 - 1.96) 
Thal phasec 2.9 1.7 2.1 1.9 2.9 1.3 0.89 (0.38 - 2.05) 1.14 (0.42 - 3.07)  0.94 (0.37 - 2.42) 0.84 (0.26 - 2.72) 
Braak NFT stagec 2.6 1.6 2.1 1.7 2.7 1.6 0.99 (0.55 - 1.77) 1.14 (0.57 - 2.27)  0.69 (0.37 - 1.31) 0.62 (0.28 - 1.37) 
Congophilic amyloid angiopathyb 53 22.5 0 0.0 5 16.1 0.47 (0.18 - 1.27) 0.47 (0.18 - 1.27)  0.36 (0.12 - 1.05) 0.33 (0.11 – 1.01) 
Neuronal loss/atrophy       
     
Neuronal lossb       
     
 
Hippocampus 21 8.8 2 12.5 1 3.3 0.87 (0.24 - 3.12) NA  0.64 (0.16 - 2.59) NA 
 
Entorhinal cortex 26 10.9 2 12.5 3 10.0 1.13 (0.40 - 3.20) 0.95 (0.26 - 3.40)  0.89 (0.29 - 2.72) 0.55 (0.13 - 2.30) 
 
Nucleus basalis 7 2.9 2 12.5 3 9.7 3.52 (1.03 - 12.05) 3.04 (0.72 - 12.79)  2.06 (0.49 - 8.68) 0.29 (0.03 - 3.06) 
 
Substantia nigra 15 6.3 2 12.5 4 12.9 2.17 (0.78 - 6.03) 2.19 (0.67 - 7.15)  1.64 (0.43 - 6.29) 1.09 (0.20 - 5.91) 
 
Locus ceruleus 12 5.0 2 12.5 0 0.0 0.83 (0.18 - 3.92) NA  0.71 (0.11 - 4.65) 
NA 
Cortical atrophy       
     
 
Any 117 52.2 7 43.8 10 35.7 0.60 (0.30 - 1.18) 0.48 (0.21 - 1.11)  0.40 (0.18 - 0.87) 0.26 (0.09 - 0.70) 
 
Temporal lobe atrophyb 36 16.4 4 25.0 1 3.7 0.82 (0.29 - 2.32) NA  0.85 (0.26 - 2.80) NA 
 Hippocampal atrophyb 38 17.3 2 12.5 1 3.7 0.41 (0.12 - 1.45) NA 
 
0.46 (0.12 - 1.80) NA 
Macroscopic cerebrovascular disease      
     
Atherosclerosisd 53 25.2 5 35.7 6 21.4 1.07 (0.50 - 2.30) 0.82 (0.31 - 2.14)  1.30 (0.54 - 3.09) 1.08 (0.36 - 3.21) 
Infarcts 61 27.9 5 33.3 5 17.2 0.82 (0.38 - 1.78) 0.58 (0.21 - 1.61)  0.68 (0.28 - 1.65) 0.52 (0.16 - 1.64) 
Lacunes 43 19.7 6 40 2 6.9 0.96 (0.41 - 2.25) 0.32 (0.07 - 1.39)  0.80 (0.31 - 2.09) 0.19 (0.04 - 1.00) 
Microscopic cerebrovascular disease      
     
Atherosclerosis 67 29.6 3 20 6 20 0.59 (0.27 - 1.31) 0.58 (0.23 - 1.50)  0.59 (0.25 - 1.41) 0.75 (0.26 - 2.13) 
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Arteriolar Sclerosis 168 70.6 8 50 20 64.5 0.60 (0.31 - 1.18) 0.69 (0.31 - 1.54)  0.61 (0.28 - 1.31) 0.76 (0.30 - 1.95) 
Cortical microinfarcts 44 25 2 15.4 6 27.3 1.12 (0.46 - 2.73) 1.52 (0.53 - 4.32) 
 
1.24 (0.44 - 3.54) 2.69 (0.76 - 9.57) 
Subcortical microinfarcts 35 19.9 3 23.1 4 18.2 1.13 (0.44 - 2.89) 1.00 (0.31 - 3.22)  0.95 (0.33 - 2.75) 0.90 (0.24 - 3.36) 
White matter pallor 89 38.4 9 60 11 36.7 1.45 (0.74 - 2.81) 0.95 (0.43 - 2.12)  1.17 (0.56 - 2.43) 0.85 (0.34 - 2.10) 
Deep white matter lesionsb 76 45.5 5 38.5 6 37.5 0.66 (0.29 - 1.51) 0.63 (0.21 - 1.87)  0.47 (0.18 - 1.23) 0.30 (0.08 - 1.12) 
Periventricular lesionsb 57 37.3 4 33.3 5 31.3 1.40 (0.59 - 3.31) 1.28 (0.41 - 3.99)  0.82 (0.31 - 2.18) 0.68 (0.19 - 2.48) 
Perivascular space expansion 170 71.1 12 75 22 71 0.88 (0.37 - 2.14) 0.79 (0.25 - 2.48)   0.94 (0.42 - 2.12) 0.70 (0.27 - 1.85) 
 
a Adjusted for age, sex, stroke, diagnosed hypertension, depression/anxiety, asthma, Parkinson’s disease, sleep problems, education, number of 
interviews, and benzodiazepine drug use. 
b Rated as moderate or severe 
c mean (SD)  
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Table 3. Adjusted odds ratios for benzodiazepine use reported before dementia and neuropathology outcomes 
 
    Benzodiazepine use, n(%) OR (95% CI), age and sex adjusted   OR (95% CI), fully adjusted
a 
Neuropathology outcome None (n=249) Once (n=16) 
Recurrent 
(n=33) 
Any 
benzodiazepine 
use 
Recurrent 
benzodiazepine 
use 
 
Any 
benzodiazepine 
use 
Recurrent 
benzodiazepine 
use 
Low brain weight 76 30.8 4 25 15 45.5 1.34 (0.70 - 2.56) 1.73 (0.82 - 3.67)  1.53 (0.73 - 3.19) 2.34 (0.98 - 5.56) 
Alzheimer’s disease pathology       
     
Intermediate/high AD neuropathologic 
change 
111 52.6 7 50.0 21 70.0 1.38 (0.69 - 2.76) 1.85 (0.79 - 4.35) 
 
1.69 (0.75 - 3.80) 2.73 (1.00 - 7.50) 
Cortical neuritic plaquesb 62 25.7 5 33.3 13 40.6 1.72 (0.88 - 3.34) 1.88 (0.87 - 4.07)  1.88 (0.87 - 4.06) 1.94 (0.79 - 4.73) 
Thal phasec 2.9 1.7 2.6 1.6 2.8 1.7 0.59 (0.26 - 1.32) 0.60 (0.24 - 1.54) 
 
0.69 (0.25 - 1.88) 1.13 (0.36 - 3.55) 
Braak NFT stagec 2.5 1.7 2.5 1.8 3.2 1.2 1.37 (0.76 - 2.46) 1.66 (0.85 - 3.27)  1.81 (0.93 - 3.53) 2.44 (1.12 - 5.31) 
Congophilic amyloid angiopathyb 50 21.3 3 20 5 15.6 0.71 (0.31 - 1.65) 0.63 (0.23 - 1.75)  0.77 (0.29 - 1.99) 0.96 (0.30 - 3.08) 
Neuronal loss/atrophy       
     
Neuronal lossb       
     
 
Hippocampus 19 8 1 7.1 4 12.5 1.19 (0.41 - 3.43) 1.34 (0.41 - 4.34)  1.25 (0.38 - 4.14) 1.85 (0.45 - 7.57) 
 
Entorhinal cortex 22 9.2 1 7.1 8 25 2.09 (0.88 - 4.98) 2.82 (1.11 - 7.18)  2.47 (0.90 - 6.76) 3.98 (1.29 - 12.34) 
 
Nucleus basalis 6 2.5 0 0 6 18.8 5.35 (1.59 - 18.03) 5.35 (1.59 - 18.03)  4.63 (1.11 - 19.24) 4.43 (1.06 - 18.46) 
 
Substantia nigra 12 5 3 20 6 18.8 4.71 (1.80 - 12.31) 4.63 (1.55 - 13.83)  3.30 (1.02 - 10.68) 5.78 (1.43 - 23.39) 
 
Locus ceruleus 11 4.6 1 6.7 2 6.3 1.46 (0.38 - 5.58) 1.35 (0.28 - 6.55)  1.44 (0.31 - 6.74) 2.10 (0.32 - 13.57) 
Cortical atrophy       
     
 
Any 108 48.4 6 46.2 20 62.5 1.26 (0.65 - 2.45) 1.52 (0.70 - 3.31)  1.62 (0.74 - 3.54) 2.47 (0.98 - 6.23) 
 
Temporal lobe atrophyb 29 13.3 2 15.4 10 31.3 2.01 (0.90 - 4.48) 2.36 (0.97 - 5.73)  2.51 (0.92 - 6.89) 2.85 (0.93 - 8.78) 
 Hippocampal atrophyb 32 14.7 0 0 9 28.1 1.15 (0.49 - 2.71) 1.15 (0.49 - 2.71) 
 
2.01 (0.69 - 5.87) 1.94 (0.66 – 5.67) 
Macroscopic cerebrovascular disease      
     
Atherosclerosisd 53 25.6 5 35.7 6 19.4 0.94 (0.44 - 2.01) 0.69 (0.27 - 1.81)  1.17 (0.48 - 2.85) 0.67 (0.21 - 2.08) 
Infarcts 55 25.5 5 33.3 11 34.4 1.59 (0.79 - 3.18) 1.62 (0.72 - 3.65)  1.89 (0.82 - 4.32) 1.84 (0.69 - 4.89) 
Lacunes 40 18.6 2 13.3 9 28.1 1.36 (0.63 - 2.94) 1.75 (0.74 - 4.15)  1.38 (0.56 - 3.44) 2.19 (0.74 - 6.45) 
Microscopic cerebrovascular disease      
     
Atherosclerosis 60 26.8 7 46.7 9 28.1 1.34 (0.68 - 2.65) 1.00 (0.43 - 2.32)  1.49 (0.67 - 3.29) 1.01 (0.38 - 2.67) 
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Arteriolar Sclerosis 166 69.5 10 66.7 20 64.5 0.66 (0.33 - 1.32) 0.62 (0.27 - 1.40)  0.79 (0.36 - 1.74) 0.75 (0.29 - 1.95) 
Cortical microinfarcts 46 26.6 4 36.4 2 7.4 0.53 (0.20 - 1.38) 0.22 (0.05 - 0.99) 
 
0.35 (0.11 - 1.13) 0.11 (0.02 - 0.63) 
Subcortical microinfarcts 35 20.2 3 27.3 4 14.8 0.86 (0.34 - 2.14) 0.65 (0.21 - 2.04)  0.86 (0.28 - 2.62) 0.59 (0.15 - 2.37) 
White matter pallor 89 38.4 9 60 11 36.7 1.17 (0.61 - 2.27) 0.82 (0.37 - 1.85)  1.17 (0.55 - 2.46) 0.79 (0.31 - 1.98) 
Deep white matter lesionsb 69 42.9 4 44.4 14 53.8 1.40 (0.66 - 2.98) 1.56 (0.66 - 3.67)  1.38 (0.58 - 3.31) 1.85 (0.67 - 5.10) 
Periventricular lesionsb 54 36.5 3 33.3 9 37.5 1.54 (0.69 - 3.46) 1.58 (0.64 - 3.91)  0.89 (0.34 - 2.28) 0.91 (0.31 - 2.70) 
Perivascular space expansion 170 71.1 9 60 25 78.1 0.91 (0.40 - 2.04) 0.94 (0.38 - 2.35)  0.91 (0.40 - 2.04) 1.30 (0.47 - 3.61) 
 
a Adjusted for age, sex, stroke, diagnosed hypertension, depression/anxiety, asthma, Parkinson’s disease, sleep problems, education, number of 
interviews, and anticholinergic drug use 
b Rated as moderate or severe 
c mean (SD)  
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